The Qilu Pharmaceutical-backed cancer, immune disorder and metabolic disease drug developer has closed a series B round led by Lilly Asia Ventures.

Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly, has led a $90m series B round for China-based oncology, metabolic disease and autoimmune disorder drug developer Regor Therapeutics. Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China also participated in the round. Founded in 2018, Regor is developing drugs to…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.